Assessing the in vivo efficacy of doxorubicin loaded hyaluronan nanoparticles.
暂无分享,去创建一个
David C. Zhu | Xuefei Huang | David C Zhu | Xuefei Huang | J. Mccormick | J. Xia | Mohammad H El-Dakdouki | Jingguang Xia | Herbert Kavunja | Jessica Grieshaber | Sandra O'Reilly | J Justin McCormick | M. El-Dakdouki | H. Kavunja | Jessica | Jessica L. Grieshaber | S. O'Reilly | Grieshaber
[1] E. Puré,et al. Development of drug loaded nanoparticles for tumor targeting. Part 2: Enhancement of tumor penetration through receptor mediated transcytosis in 3D tumor models. , 2013, Nanoscale.
[2] Yaping Li,et al. Overcoming multidrug resistance (MDR) in cancer by nanotechnology , 2010 .
[3] A. V. D. Van Der Zee,et al. Turning promise into progress for antiangiogenic agents in epithelial ovarian cancer. , 2012, Critical reviews in oncology/hematology.
[4] M. Gore,et al. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. , 1990, Gynecologic oncology.
[5] Timothy A. Yap,et al. Beyond chemotherapy: targeted therapies in ovarian cancer , 2009, Nature Reviews Cancer.
[6] S. Pignata,et al. Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] R. Agarwal,et al. Ovarian cancer: strategies for overcoming resistance to chemotherapy , 2003, Nature Reviews Cancer.
[8] F. Szoka,et al. A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas , 2006, Proceedings of the National Academy of Sciences.
[9] F. Gao,et al. The reversal effect of magnetic Fe3O4 nanoparticles loaded with cisplatin on SKOV3/DDP ovarian carcinoma cells , 2009, International journal of nanomedicine.
[10] David C. Zhu,et al. Hyaluronic acid immobilized magnetic nanoparticles for active targeting and imaging of macrophages. , 2010, Bioconjugate chemistry.
[11] F. Gao,et al. Reversal of multidrug resistance by magnetic Fe3O4 nanoparticle copolymerizating daunorubicin and 5-bromotetrandrine in xenograft nude-mice , 2009, International journal of nanomedicine.
[12] B. Goff,et al. Ovarian carcinoma diagnosis , 2000, Cancer.
[13] David C. Zhu,et al. CD44 Targeting Magnetic Glyconanoparticles for Atherosclerotic Plaque Imaging , 2013, Pharmaceutical Research.
[14] F. Gao,et al. Reversal in multidrug resistance by magnetic nanoparticle of Fe3O4 loaded with adriamycin and tetrandrine in K562/A02 leukemic cells , 2008, International journal of nanomedicine.
[15] P. Neven,et al. Intraperitoneal chemotherapy in patients with advanced ovarian cancer: the con view. , 2008, The oncologist.
[16] Robert C. Bast,et al. The biology of ovarian cancer: new opportunities for translation , 2009, Nature Reviews Cancer.
[17] I. Tannock,et al. Drug penetration in solid tumours , 2006, Nature Reviews Cancer.
[18] Robert S Mannel,et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] David C. Zhu,et al. Glyconanoparticle aided detection of β-amyloid by magnetic resonance imaging and attenuation of β-amyloid induced cytotoxicity. , 2013, ACS chemical neuroscience.
[20] J. Huober,et al. Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy--a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6). , 2007, Gynecologic oncology.
[21] Taeghwan Hyeon,et al. Designed synthesis of uniformly sized iron oxide nanoparticles for efficient magnetic resonance imaging contrast agents. , 2012, Chemical Society reviews.
[22] B. Monk,et al. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[23] M. Gore,et al. Intraperitoneal chemotherapy in ovarian cancer remains experimental. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] B. Hennessy,et al. Molecular Targeted Therapy in Ovarian Cancer , 2011, Drugs.
[25] R. Mumper,et al. Anthracycline Nano-Delivery Systems to Overcome Multiple Drug Resistance: A Comprehensive Review. , 2013, Nano today.
[26] Michael F. Flessner,et al. Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence , 2010, Nature Reviews Clinical Oncology.
[27] David C. Zhu,et al. A simple method for the synthesis of hyaluronic acid coated magnetic nanoparticles for highly efficient cell labelling and in vivo imaging. , 2011, RSC advances.
[28] Lothar Lilge,et al. The Distribution of the Anticancer Drug Doxorubicin in Relation to Blood Vessels in Solid Tumors , 2005, Clinical Cancer Research.
[29] M. Piccart-Gebhart,et al. New therapies for ovarian cancer: cytotoxics and molecularly targeted agents. , 2008, Critical reviews in oncology/hematology.
[30] Xing-jie Liang,et al. Biomedical nanomaterials for imaging-guided cancer therapy. , 2012, Nanoscale.
[31] David C. Zhu,et al. Synthesis of β-cyclodextrin conjugated superparamagnetic iron oxide nanoparticles for selective binding and detection of cholesterol crystals. , 2012, Chemical communications.
[32] A. Oza,et al. Sorafenib in Combination With Gemcitabine in Recurrent Epithelial Ovarian Cancer: A Study of the Princess Margaret Hospital Phase II Consortium , 2010, International Journal of Gynecologic Cancer.
[33] D. Chi,et al. Epithelial Ovarian Cancer: Focus on Targeted Therapy , 2011, Journal of oncology.
[34] David C. Zhu,et al. Development of multifunctional hyaluronan-coated nanoparticles for imaging and drug delivery to cancer cells. , 2012, Biomacromolecules.
[35] Anna Moore,et al. Magnetic Nanoparticles for Cancer Diagnosis and Therapy , 2012, Pharmaceutical Research.
[36] E. Puré,et al. Development of drug loaded nanoparticles for tumor targeting. Part 1: Synthesis, characterization, and biological evaluation in 2D cell cultures. , 2013, Nanoscale.
[37] R. Mohan,et al. Nanoparticles in the treatment and diagnosis of neurological disorders: untamed dragon with fire power to heal. , 2012, Nanomedicine : nanotechnology, biology, and medicine.
[38] H. Imhof,et al. Superparamagnetic particles as oral contrast medium in magnetic resonance imaging of patients with treated ovarian cancer--comparison with plain MRI. , 1993, The British journal of radiology.
[39] K. Ulbrich,et al. The pharmacokinetics of polymer-bound adriamycin. , 1990, Biochemical pharmacology.
[40] M. Ferrari. Cancer nanotechnology: opportunities and challenges , 2005, Nature Reviews Cancer.
[41] M. Markman. Strategies to examine new compounds for intraperitoneal use in ovarian cancer , 2008, International Journal of Gynecologic Cancer.
[42] F. Gao,et al. Reversal of multidrug resistance by cisplatin-loaded magnetic Fe3O4 nanoparticles in A549/DDP lung cancer cells in vitro and in vivo , 2013, International journal of nanomedicine.
[43] David C. Zhu,et al. Magnetic glyco-nanoparticles: a tool to detect, differentiate, and unlock the glyco-codes of cancer via magnetic resonance imaging. , 2010, Journal of the American Chemical Society.
[44] H. Pinedo,et al. Doxorubicin compared with related compounds in a nude mouse model for human ovarian cancer. , 1990, European journal of cancer.
[45] Cyndee Gruden,et al. Magnetic glyco-nanoparticles: a unique tool for rapid pathogen detection, decontamination, and strain differentiation. , 2007, Journal of the American Chemical Society.
[46] Taeghwan Hyeon,et al. Inorganic Nanoparticles for MRI Contrast Agents , 2009 .
[47] Monya Baker,et al. Nanotechnology imaging probes: smaller and more stable , 2010, Nature Methods.
[48] M. Gore,et al. The future of targeted therapies in ovarian cancer. , 2009, The oncologist.